Neurogene Inc. (NGNE): Total Liabilities
$23.72M
As of 2025-12-31
$27.23M
As of 2026-06-30
+30.6%
3-year compound annual growth
+4.2%
5-year compound annual growth
+17.0%
10-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $23.72M | -6.5% | 2026-03-24, Balance as of period end |
| 2024-12-31 | $25.36M | -30.6% | 2026-03-24, Balance as of period end |
| 2023-12-31 | $36.55M | +243.6% | 2025-03-24, Balance as of period end |
| 2022-12-31 | $10.64M | -47.9% | 2024-03-18, Balance as of period end |
| 2021-12-31 | $20.40M | +5.7% | 2023-03-20, Balance as of period end |
| 2020-12-31 | $19.30M | +261.8% | 2022-03-01, Balance as of period end |
| 2019-12-31 | $5.34M | +7.9% | 2021-03-25, Balance as of period end |
| 2018-12-31 | $4.95M | -56.8% | 2020-03-12, Balance as of period end |
| 2017-12-31 | $11.44M | +17.8% | 2019-03-07, Balance as of period end |
| 2016-12-31 | $9.72M | +97.4% | 2018-03-12, Balance as of period end |
| 2015-12-31 | $4.92M | -6.7% | 2017-03-09, Balance as of period end |
| 2014-12-31 | $5.28M | -29.5% | 2016-03-14, Balance as of period end |
| 2013-12-31 | $7.48M | n/a | 2015-03-16, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Neurogene Inc. (NGNE) | 2025-12-31 | $23.72M | -6.5% |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $71.53B | -6.1% |
| TherapeuticsMD, Inc. (TXMD) | 2025-12-31 | $10.78M | -5.9% |
| Pfizer Inc (PFE) | 2025-12-31 | $121.39B | -2.8% |
| Johnson & Johnson (JNJ) | 2025-12-28 | $117.67B | +8.3% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $99.59M | +24.7% |
| Provectus Biopharmaceuticals, Inc. (PVCT) | 2025-12-31 | $7.00M | +0.4% |
| Lisata Therapeutics, Inc. (LSTA) | 2025-12-31 | $3.14M | -44.7% |
| Heron Therapeutics, Inc. (HRTX) | 2025-12-31 | $241.54M | -9.5% |
Compare NGNE, BMY, TXMD, PFE side by side · Screen every company in Pharmaceutical Preparations ↗